

2019-163 - FOI Request - Biosimilar biologic therapies

1. Does your Trust use the following biosimilar biologic therapies? If possible, how many patients are currently being treated?	
Adalimumab [Hyrimoz]	No.
Adalimumab [Amgevita]	Yes, 13 patients.
Adalimumab [Imraldi]	No.
Adalimumab [Hulio]	
Etanercept [Benepali]	Yes, 25 patients.
Etanercept [Erelzi]	No.
Infliximab [Inflectra]	Yes, 70 patients.
Infliximab [Remsima]	No.
Infliximab [Flixabi]	
2a. Within your rheumatology department how many patients in the year 2018 were treated with a biologic or JAK2?	233 patients.
2b. Within your rheumatology department how many patients in the year 2018 were treated with a DMARD? [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]	337 patients.
3a. Within your dermatology department how many patients in the year 2018 were treated with a biologic or JAK2?	None.
3b. Within your dermatology department how many patients in the year 2018 were treated with a DMARD? [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]	219 patients.
4a. Within your gastroenterology department how many patients in the year 2018 were treated with a biologic or JAK2?	286 patients.
4b. Within your gastroenterology department how many patients in the year 2018 were treated with a DMARD? [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]	162 patients.
5. Does your trust record the DAS score electronically on the patient records? If so how many are DAS 5+?	Recorded in paper case notes and letters.